Khattar Jack A. 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Oct 10, 2025
Insider Transaction Report
Form 4
Khattar Jack A.
DirectorPresident, CEO
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-10-09−81,250→ 0 totalExercise: $25.30From: 2018-02-24Exp: 2027-02-24→ Common Stock (81,250 underlying) - Sale
Common Stock
2025-10-09$50.55/sh−58,371$2,950,654→ 1,208,107 total - Exercise/Conversion
Common Stock
2025-10-09$25.30/sh+81,250$2,055,625→ 1,266,478 total - Sale
Common Stock
2025-10-09$51.46/sh−1,529$78,682→ 1,206,578 total
Holdings
- 1,005,600(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.11 to $51.09. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.14 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The option vests in four equal installments beginning on February 24, 2018